Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | LOX | P28300 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17300244 | 0.94 | TTK (0.39) | TTKNR1H2NR1H3CA12CA1 | |
| SCHEMBL17300240 | 0.94 | TDP1 (0.40) | TTKNR1H2NR1H3TDP1DHODH | |
| SCHEMBL17300238 | 0.91 | TDP1 (0.42) | TDP1DHODH | |
| SCHEMBL17300235 | 0.91 | TTK (0.40) | TTKTDP1DHODHLOX | |
| SCHEMBL17300245 | 0.88 | TDP1 (0.41) | TTKCA12CA1CA2CA9 | |
| SCHEMBL17300247 | 0.87 | TDP1 (0.46) | TDP1DHODH | |
| SCHEMBL17300234 | 0.87 | HTR6 (0.42) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL20249688 | 0.83 | NR1H2 (0.42) | TTKNR1H2NR1H3CA12CA1 | |
| SCHEMBL17914887 | 0.83 | ADORA2A (0.39) | TDP1DHODH | |
| SCHEMBL17300201 | 0.83 | DHODH (0.42) | TDP1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10608189-B2 | Condensed cyclic compounds and organic light-emitting devices including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-03-31 | — | — | US | disclosed |
| US-20150349275-A1 | CONDENSED CYCLIC COMPOUNDS AND ORGANIC LIGHT-EMITTING DEVICES INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2015-12-03 | — | — | US | disclosed |
| US-20150349275-A1 | CONDENSED CYCLIC COMPOUNDS AND ORGANIC LIGHT-EMITTING DEVICES INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10608189-B2 | Condensed cyclic compounds and organic light-emitting devices including the same | CRY1, CRY2, CCNE2 | TTK 3879/4885NR1H2 618/4885NR1H3 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.